Industry News

Broad Adenovector Gene Therapy Patent Announced

Published in Gene Therapy Weekly, August 17th, 2000

GenVec, Inc., Gaithersburg, Maryland, announced the company was issued a U.S. patent broadly covering replication-deficient adenovectors that are free of replication competent adenovirus.

Such preparations are often referred to as "replication-competent-adenovirus-free" or "RCA-free" adenovectors, and provide significant advantages when used as tools for new product discovery and for therapeutic applications.

"The field of gene therapy has expended substantial efforts to create RCA-free adenovectors," said Dr. Paul H. Fischer, GenVec. "We are pleased that GenVec received this broad patent that recognizes our pioneering efforts in this area. This...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry